Who
Ourania Tatsis
EVP, Chief Reg. & Quality Off.
Company insider
Files Form 4 as: EVP, Chief Reg. & Quality Off., Vertex Pharmaceuticals; Director, Odyssey Therapeutics; Director, Verve Therapeutics.
In numbers
- Trades disclosed
- 171
- Buys
- 0
- Sells
- 42
- Bought
- $0
- Sold
- $25.8M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 1 Oct 2019
- Last trade
- 21 Jul 2026
- Last filed
- 23 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 21 Jul 2026filed 23 Jul 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —8,251 at $0.00 | filing |
| 21 Jul 2026filed 23 Jul 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —8,251 at $0.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $787K1,500 at $524.99 | filing |
| 2 Jul 2026filed 7 Jul 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $787K1,500 at $524.99 | filing |
| 7 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,393 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | ODTX Odyssey Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —27,393 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $126K260 at $486.35 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $126K260 at $486.35 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $789K1,627 at $485.11 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $789K1,627 at $485.11 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $174K368 at $473.68 | filing |
| 18 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $174K368 at $473.68 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,789 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.1M2,294 at $483.75 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $298K609 at $489.46 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,789 at $0.00 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.1M2,294 at $483.75 | filing |
| 17 Feb 2026filed 19 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $298K609 at $489.46 | filing |
| 13 Feb 2026filed 18 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Code F | $1.9M3,804 at $487.76 | filing |
| 13 Feb 2026filed 18 Feb 2026 | VRTX Vertex PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $750K1,500 at $499.99 | filing |
News
Head to Head Analysis: Caribou Biosciences (NASDAQ:CRBU) & Vertex Pharmaceuticals (NASDAQ:VRTX)VRTX · tickerreport.com · 14 Oct 2026Vertex Pharmaceuticals Incorporated: Vertex to Present New Data on ALYFTREK at the North American Cystic Fibrosis ConferenceVRTX · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Ourania Tatsis; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.